leon nanodrugs GmbH, a Munich, Germany-based nanotechnology-based drug development company, closed an €18.5m Series A funding.
The round was led by TVM Capital Life Science, with participation from Signet Healthcare Partners (USA), LifeCare Partners (Switzerland), CD-Venture (Germany), Albany Private Equity Holding (Australia), and a non-disclosed Family Office from Germany. Dr. Hubert Birner, Managing Partner, and Stefan Fischer, General Partner & CFO, TVM Capital Life Science,James Gale, Managing Director, Signet Healthcare Partners, Dr. Gerhard Ries, Managing Partner, LifeCare Partners, Dr. Frank Mathias, CEO, Medigene AG, and Dr. Bernd Baumstümmler, CEO, Instillo Group, will be joining the Board of Directors, in conjunction with the funding.
The company will use the funds to expand its service business and to enter into high margin co-development deals with pharmaceutical partners.
Led by Dr. Wolfgang Beier and Cornelia Beier, leon-nanodrugs develops novel oral and parenteral formulations by using GMP (Good Manufacturing Practice) compliant nanotechnology to improve bioavailability, solubility as well as dissolution rates.